Unraveling myasthenia gravis immunopathogenesis using animal models

Drug Discovery Today: Disease Models

Volumn 3, Issue 1, 2006, Pages 15-20

  Tüzün, Erdem ^a   Christadoss, Premkumar ^a  

^a University of Texas Medical Branch School of Medicine   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ANTIBODY; CD4 ANTIBODY; CHOLINERGIC RECEPTOR; COMPLEMENT MEMBRANE ATTACK COMPLEX; ETANERCEPT; GAMMA INTERFERON; INTERLEUKIN 10; MONOCLONAL ANTIBODY; TRANSFORMING GROWTH FACTOR BETA; UNCLASSIFIED DRUG;

ADOPTIVE IMMUNOTHERAPY; AUTOIMMUNE DISEASE; B LYMPHOCYTE; CELLULAR IMMUNITY; COMPUTER MODEL; DENDRITIC CELL; DRUG DELIVERY SYSTEM; IMMUNOPATHOGENESIS; IN VITRO STUDY; IN VIVO STUDY; INTERMETHOD COMPARISON; KNOCKOUT MOUSE; MOLECULAR DYNAMICS; MYASTHENIA GRAVIS; NONHUMAN; NUCLEOTIDE SEQUENCE; REVIEW; T LYMPHOCYTE; TRANSGENIC MOUSE;

EID: 33645879218     PISSN: 17406757     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.ddmod.2006.03.013     Document Type: Review

References (20)

1. Burkhardt H., and Kalden J.R. Animal models of autoimmune diseases. Rheumatol. Int. 17 (1997) 91-99
2. Lennon V.A. The immunopathology of myasthenia gravis. Hum. Pathol. 9 (1978) 541-551
3. Pachner A.R. Experimental models of myasthenia gravis: lessons in autoimmunity and progress toward better forms of treatment. Yale J. Biol. Med. 60 (1987) 169-177
4. Patrick J., and Lindstrom J. Autoimmune response to acetylcholine receptor. Science 180 (1973) 871-872
5. Christadoss P., et al. Animal models of myasthenia gravis. Clin. Immunol. 94 (2000) 75-87
6. Link H., and Xiao B.G. Rat models as tool to develop new immunotherapies. Immunol. Rev. 184 (2001) 117-128
7. Christadoss P., and Dauphinee M.J. Immunotherapy for myasthenia gravis: a murine model. J. Immunol. 136 (1986) 2437-2440
8. Christadoss P. Immunogenetics of experimental autoimmune myasthenia gravis. Crit. Rev. Immunol. 9 (1989) 247-278
9. Tuzun E., et al. Genetic evidence for involvement of classical complement pathway in induction of experimental autoimmune myasthenia gravis. J. Immunol. 171 (2003) 3847-3854
10. Lindstrom J.M., et al. Pathological mechanisms in experimental autoimmune myasthenia gravis. II. Passive transfer of experimental autoimmune myasthenia gravis in rats with anti-acetylcholine receptor antibodies. J. Exp. Med. 144 (1976) 739-753
11. Tarrab-Hazdai R., et al. Experimental autoimmune myasthenia induced in monkeys by purified acetylcholine receptor. Nature 256 (1975) 128-130
12. Shelton G.D., et al. Canine and human myasthenia gravis autoantibodies recognize similar regions on the acetylcholine receptor. Neurology 38 (1988) 1417-1423
13. Yang H., et al. Mapping myasthenia gravis-associated T cell epitopes on human acetylcholine receptors in HLA transgenic mice. J. Clin. Invest. 109 (2002) 1111-1120
14. Poussin M.A., et al. B7-1 costimulatory molecule is critical for the development of experimental autoimmune myasthenia gravis. J. Immunol. 170 (2003) 4389-4396
15. Christadoss P., and Goluszko E. Myasthenia gravis. In: Kuchroo V.K., et al. (Ed). Cytokines and Autoimmune Disease (1987), Humana Press 373-385
16. Vernet-der Garabedian B., et al. Protective effect of myasthenic immunoglobulins against the lethal toxicity of alpha bungarotoxin. Clin. Exp. Immunol. 68 (1987) 130-137
17. Kuncl R.W., et al. 3-Deazaadenosine: a therapeutic strategy for myasthenia gravis by decreasing the endocytosis of acetylcholine receptors. J. Pharmacol. Exp. Ther. 267 (1993) 582-589
18. Tzartos S.J., et al. The main immunogenic region of the acetylcholine receptor. Structure and role in myasthenia gravis. Autoimmunity 8 (1991) 259-270
19. Rowin J., et al. Etanercept treatment in corticosteroid-dependent myasthenia gravis. Neurology 63 (2004) 2390-2392
20. Vincent A., and Leite M.I. Neuromuscular junction autoimmune disease: muscle specific kinase antibodies and treatments for myasthenia gravis. Curr. Opin. Neurol. 18 (2005) 519-525